<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>diagnostic imaging comparison &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/diagnostic-imaging-comparison/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 27 Oct 2025 15:35:21 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>diagnostic imaging comparison &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Groundbreaking Study Poised to Revolutionize Diagnosis of Britain’s Leading Cancer</title>
		<link>https://bioengineer.org/groundbreaking-study-poised-to-revolutionize-diagnosis-of-britains-leading-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 27 Oct 2025 15:35:08 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[clinical trial MEDLEY study]]></category>
		<category><![CDATA[diagnostic imaging comparison]]></category>
		<category><![CDATA[low-dose CT scans]]></category>
		<category><![CDATA[lung cancer early detection]]></category>
		<category><![CDATA[UK healthcare innovation]]></category>
		<guid isPermaLink="false">https://bioengineer.org/groundbreaking-study-poised-to-revolutionize-diagnosis-of-britains-leading-cancer/</guid>

					<description><![CDATA[A groundbreaking clinical study has commenced recruitment with the ambition to revolutionize the early detection of lung cancer, a disease that remains the leading cause of cancer mortality worldwide and in the UK. This innovative research targets communities across Leeds, Bath, Hull, and Stoke-on-Trent, funded by the National Institute for Health and Care Research (NIHR). [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">287167</post-id>	</item>
		<item>
		<title>18F-FAPI PET/CT Reveals Lung Cancer Brain Metastasis Rates</title>
		<link>https://bioengineer.org/18f-fapi-pet-ct-reveals-lung-cancer-brain-metastasis-rates/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 21 Oct 2025 11:38:28 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[18F-FAPI PET/CT imaging]]></category>
		<category><![CDATA[brain metastasis detection rates]]></category>
		<category><![CDATA[diagnostic imaging comparison]]></category>
		<category><![CDATA[fibroblast activation protein inhibitors]]></category>
		<category><![CDATA[lung cancer brain metastasis]]></category>
		<guid isPermaLink="false">https://bioengineer.org/18f-fapi-pet-ct-reveals-lung-cancer-brain-metastasis-rates/</guid>

					<description><![CDATA[A groundbreaking study published in BMC Cancer introduces novel insights into the detection of brain metastases (BM) originating from various pathological types of lung cancer using fluorine-18-fibroblast activation protein inhibitor positron emission tomography/computed tomography (^18F-FAPI PET/CT). This pioneering research reveals distinct differences in diagnostic efficacy across lung cancer subtypes, potentially reshaping prognostic evaluation and patient [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">284292</post-id>	</item>
	</channel>
</rss>
